Showing results (861-870 of 943) with videos related to

Sort By:
Pageof 95
Acta Orthopaedica|July 23, 2025
Antimicrobial resistance in orthopedics: microbial insights, clinical impact, and the necessity of a multidisciplinary approach-a reviewJulia L Van Agtmaal, Mariëlle Verheul, Lieve Vonken, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 27, 2025
Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidaseNicola Colclough, Alexandra L Orton, Scott Martin, et al.
The Journal of Invasive Cardiology|May 13, 2025
Artificial intelligence for chronic total occlusion percutaneous coronary interventionsAthanasios Rempakos, Pranathi Pilla, Michaella Alexandrou, et al.
Neuro-Oncology|October 30, 2020
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography studyAurelija Jucaite, Per Stenkrona, Zsolt Cselényi, et al.
Circulation Research|December 25, 2013
Preclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1α analog in a translational ovine myocardial infarction modelJohn W Macarthur, Jeffrey E Cohen, Jeremy R McGarvey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 13, 2025
Barriers, facilitators, and best practices for successful vaping prevention campaigns for sexual and gender minority youthKate Okker-Edging, Jenine Pilla, Andy S L Tan, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.
Cancer Immunology, Immunotherapy : CII|October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsLorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
Journal of the National Cancer Institute|March 20, 2026
Clinician validation of the Medicare measure for potentially avoidable hospital visits after chemotherapyArthur S Hong, Michael D Dang, Vincent Merrill, et al.
Pageof 95